soul trial oral semaglutide cardiovascular outcomes nejm 2025 results New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Cardiovascular Outcomes Associated with Semaglutide

While public health experts and climate scientists argue about whether we should rely on livestock production systems to meet the nutritional demands of a growing global population while tackling climate change, those who produce our foodthe average farmerare struggling financially (Wiggins et al., 2010)

Clients can enjoy their Hydration boost Facials for glowing skin, flawless nail extensions, and expert brow and lash lifts or tints

The STEP 4 trial showed that patients who stopped semaglutide began regaining weight, whereas those who continued treatment maintained or further reduced their weight

Trends Cardiovasc